- Home
- PDO vs VCEL Comparison
PDO vs VCEL Comparison
Compare PDO & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PDO | VCEL |
|---|---|---|
| Founded | 2020 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | PDO | VCEL |
|---|---|---|
| Price | $12.81 | $35.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.75 |
| AVG Volume (30 Days) | ★ 694.5K | 624.8K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 11.80% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | N/A | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $12.37 | $28.95 |
| 52 Week High | $14.25 | $45.97 |
Technical Indicators
Market Signals| Indicator | PDO | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 52.98 |
| Support Level | $12.60 | $33.91 |
| Resistance Level | $14.13 | $38.31 |
| Average True Range (ATR) | 0.15 | 1.87 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 26.92 | 35.26 |
Price Performance
Historical ComparisonAbout PDO PIMCO Dynamic Income Opportunities Fund of Beneficial Interest
PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.